# Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

> **NCT02391727** · PHASE1 · COMPLETED · sponsor: **Synermore Biologics Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Colon Cancer, Breast Cancer, Cancer of the Head and Neck

## Interventions

- **BIOLOGICAL:** SYN004

## Key facts

- **NCT ID:** NCT02391727
- **Lead sponsor:** Synermore Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391727, "Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02391727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*